BEAT BioTherapeutics Appoints Dr. Sam L. Teichman As Chief Medical Officer
Published: Mar 24, 2014
SEATTLE--(BUSINESS WIRE)--BEAT BioTherapeutics Corp. (BEATBio) announced today the appointment of Sam L. Teichman, MD, FACC, FESC, FACP, as Chief Medical Officer (CMO) and Director. BEATBio is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure.
Help employers find you! Check out all the jobs and post your resume.